Cargando…
Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
Recurrent cervical cancer has a grim prognosis with 5-year survival <5%. Current treatment options are limited; standards of care such as palliative chemotherapy and surgical resection often provide a small survival advantage. To date, only one targeted agent has FDA approval for the treatment of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626235/ https://www.ncbi.nlm.nih.gov/pubmed/36330376 http://dx.doi.org/10.1155/2022/6579715 |